Skip to Main Content

Rise and shine, everyone, the middle of the week is already here. Time flies when you’re having … fill in the blank here. Meanwhile, a hazy, muggy morning is unfolding here on the Pharmalot campus, where the official mascot is noisily snoozing and the short people are otherwise gainfully occupied. As for us, we are downing yet another needed cup of stimulation. Our choice today is coconut. No kidding. Feel free to join us, as always. And here are some tidbits to help you along. Have a wonderful day and keep in touch …

A combination of AstraZeneca’s (AZN) lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with stage 4 non-small cell lung cancer and high levels of gene mutations, Reuters reports. The late-stage clinical trial was testing Imfinzi along with another treatment called tremelimumab and compared the combination to platinum-based chemotherapy to treat patients whose cancer had spread beyond the lungs. The study did not meet the main goal of improving overall survival in the primary group.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Kudos to our scribe for a fulsome Pharmalittle. Indeed, “a much welcomed fillip” at the beginning of the business day. (And I needed to look that word up to be sure it wasn’t a typo – you learn something new here every day, yes?}

Comments are closed.